Study of a Pandemic Influenza Vaccine
NCT00136331 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 400
Last updated 2016-07-19
Summary
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is the leading candidate to cause the next avian influenza pandemic. This study will test the safety and immunogenicity of a H5N1 pandemic influenza vaccine in healthy adults.
Conditions
Interventions
- BIOLOGICAL
-
Pandemic influenza vaccine
Sponsors & Collaborators
-
Seqirus
lead INDUSTRY
Principal Investigators
-
Terry M Nolan · Murdoch Childrens Research Institute
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2005-10-31
- Completion
- 2006-11-30
Countries
- Australia
Study Locations
More Related Trials
-
Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults
NCT00545701 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine
NCT01443663 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above
NCT00319098 ·Status: COMPLETED ·Phase: PHASE3
-
Universal Influenza A Vaccine in Healthy Adults
NCT05155319 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older
NCT06507553 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally
NCT00489931 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults
NCT01776541 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly
NCT00296829 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age
NCT00309647 ·Status: COMPLETED ·Phase: PHASE1
-
Pandemic Influenza Plasmid DNA Vaccines (Needle)
NCT00709800 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
NCT01766921 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects
NCT00356798 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years
NCT00309634 ·Status: COMPLETED ·Phase: PHASE1
-
Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults
NCT00516035 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules
NCT00652743 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
NCT02839330 ·Status: COMPLETED ·Phase: PHASE3
-
T and B Cell Response to Avian Flu Vaccine
NCT00337896 ·Status: COMPLETED
-
Safety Study of an Oral Vaccine to Prevent Avian Influenza
NCT01335347 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1b Influenza Vaccine Study in Healthy Subjects
NCT01181336 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.
NCT00755703 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old
NCT01236040 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years
NCT01560793 ·Status: COMPLETED ·Phase: PHASE1
-
Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults
NCT00488046 ·Status: COMPLETED ·Phase: PHASE1
-
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2
NCT01596725 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
NCT07128615 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2